50th ASH Annual Meeting and Exposition (December 6 - 9, 2008): Mechanism of Disease and Novel Therapeutics for Sickle Cell Vasculopathy

Before you can access ASH's online program, you must agree to the following:

Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
For the research and study to be eligible for presentation at the ASH annual meeting, information contained in the abstract, as well as additional data and information to be presented about the research and/or study at the annual meeting, may not be made public before the abstract has been published/presented at the ASH annual meeting.

Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

Mechanism of Disease and Novel Therapeutics for Sickle Cell Vasculopathy

Saturday, December 6, 2008: 2:00 PM-3:30 PM

Yerba Buena Ballroom Salons 7-8 (San Francisco Marriott)

Sunday, December 7, 2008: 7:30 AM-9:00 AM

Yerba Buena Ballroom Salons 7-8 (San Francisco Marriott)

Mechanisms of Vasculopathy in Sickle Cell Disease and Thalassemia

Claudia R. Morris, MD

Children's Hospital and Research Center Oakland, Oakland, CA

Novel Small-Molecule Therapeutics for Sickle Cell Disease: Nitric Oxide, Carbon Monoxide, Nitrite, and Apolipoprotein A

Gregory J. Kato, MD

Pulmonary and Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD

New Advances in Stem Cell and Gene Therapy for Sickle Cell Disease

Tim M. Townes, PhD

University of Alabama at Birmingham, Birmingham, AL

See more of: Education Program

<< Previous Session | Next Session >>